UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./
March 15, 2016 10:21 AM EDTIn the news release, Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information, issued 15-Mar-2016 by Valeant Pharmaceuticals International, Inc. over PR Newswire, we are advised by the Company that under the "Next Four Quarters (Second Quarter 2016 - First Quarter 2017) Guidance" section, the third bullet should read "Adjusted EBITDA (non-GAAP) expected to be ~$6.0 billion" rather than "Adjusted EBITDA (non-GAAP) expected to be ~$6.2 - $6.6 billion" as originally issued inadvertently. The complete, corrected release follows:
Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial InformationCompany Provides New 2016 Guidance
LAVAL, Quebec, March 15, 2016 /PRNewswire/ --Â Valeant... More
